2016 saw 30 new active substances approved in the EU, in a total of 29 different products, of which 10 were for cancer indications. Two companies shared the honors for productivity: AstraZeneca and Lilly each saw three new active substances approved by the European Commission during the year.
Cancer drugs increased their share of EU initial marketing authorizations in 2016, accounting for a third of the 30 new active substances approved by the European Commission.
Although the total number of new active substances (NASs) in 2016 was significantly down on the high of 46 seen...